Pyxis Oncology Statistics
Share Statistics
Pyxis Oncology has 59.47M shares outstanding. The number of shares has increased by 34.07% in one year.
| Shares Outstanding | 59.47M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 41.13M |
| Failed to Deliver (FTD) Shares | 75 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 5.86M, so 9.85% of the outstanding shares have been sold short.
| Short Interest | 5.86M |
| Short % of Shares Out | 9.85% |
| Short % of Float | 13.31% |
| Short Ratio (days to cover) | 10.78 |
Valuation Ratios
The PE ratio is -0.97 and the forward PE ratio is -3.88.
| PE Ratio | -0.97 |
| Forward PE | -3.88 |
| PS Ratio | 0 |
| Forward PS | 242.2 |
| PB Ratio | 0.57 |
| P/FCF Ratio | -0.93 |
| PEG Ratio | n/a |
Enterprise Valuation
Pyxis Oncology Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.84, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.84 |
| Quick Ratio | 4.84 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.97 |
| Cash Flow / Debt | -57.39 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.59% and return on capital (ROIC) is -55.9%.
| Return on Equity (ROE) | -0.59% |
| Return on Assets (ROA) | -0.42% |
| Return on Capital (ROIC) | -55.9% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.37M |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -5.78% in the last 52 weeks. The beta is 1.28, so Pyxis Oncology 's price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | -5.78% |
| 50-Day Moving Average | 3.13 |
| 200-Day Moving Average | 3.8 |
| Relative Strength Index (RSI) | 28.96 |
| Average Volume (20 Days) | 1.21M |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of $0 and earned -$73.79M in profits. Earnings per share was $-1.85.
| Revenue | 0 |
| Gross Profit | -2.00M |
| Operating Income | -82.20M |
| Net Income | -73.79M |
| EBITDA | -78.49M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.85 |
Balance Sheet
The company has $9.66M in cash and $21.33M in debt, giving a net cash position of -$11.67M.
| Cash & Cash Equivalents | 9.66M |
| Total Debt | 21.33M |
| Net Cash | -11.67M |
| Retained Earnings | -286.23M |
| Total Assets | 195.31M |
| Working Capital | 128.55M |
Cash Flow
In the last 12 months, operating cash flow was -$70.71M and capital expenditures -$6.73M, giving a free cash flow of -$77.44M.
| Operating Cash Flow | -70.71M |
| Capital Expenditures | -6.73M |
| Free Cash Flow | -77.44M |
| FCF Per Share | -1.94 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PYXS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -113.5% |
| FCF Yield | -79.94% |
Analyst Forecast
The average price target for PYXS is $10, which is 513.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 513.5% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -1.29 |
| Piotroski F-Score | 3 |